RubrYc Therapeutics, Inc., is a biotechnology company applying proprietary machine-learning solutions to discover epitope-selective biologics. Inspired by recent advances in molecular library synthesis, massively parallel screening and computing, RubrYc is forging a new path for information-driven discovery of epitope-targeted drug candidates. RubrYc deploys our artificial intelligence and molecular engineering capabilities in the ELS System:
1. Epitope: discover and develop Meso-scale Engineered Molecules (MEMs), our proprietary antigens that embody prescribed epitopes
2. Library: design, produce, and select focused immune repertoires unique to each campaign (in vivo & in vitro)
3. Screen: Phage to Mammalian display for high-affinity, high-expression, high-stability clones
RubrYc is a flexible and reliable discovery partner, accommodating multiple partnership models covering the span of biologics discovery activities. We will raise Series B to advance pipeline and go to clinic.